The answer so far
MOTS-c is a short peptide associated with mitochondrial DNA and studied as a possible metabolic signal. Researchers have measured the body’s own MOTS-c during exercise and tested the peptide in animals. That does not establish that a MOTS-c product improves human fitness, energy or ageing.12
On this page
Why are people interested in MOTS-c?
MOTS-c appears in discussions of exercise, metabolic health and ageing. The idea is appealing: if a small molecule is involved when muscles respond to exertion, perhaps understanding it could lead to useful treatments. The research question is reasonable, but a signal observed during exercise and a product that recreates exercise’s benefits are different things. Follow the human and mouse studies.1
What is a mitochondrial peptide?
Mitochondria are structures in cells that help turn nutrients into usable energy and participate in many other processes. MOTS-c is a short chain of 16 amino acids whose genetic instructions are associated with mitochondrial DNA. Researchers study it as a possible signal involved in how cells respond to metabolic stress. Its normal biology does not tell us what an outside product will do at a different concentration, route or duration.12
What has been studied in people and animals?
A 2021 study measured the body’s own MOTS-c around exercise in ten healthy young men; it did not give them a MOTS-c product. In separate experiments, mice given MOTS-c showed changes in some measures of physical performance. These results support further research but cannot establish a benefit for human energy, fitness, weight or ageing. Two authors disclosed consulting and shareholding interests in a biotechnology company. See exactly what each part measured.1
Is MOTS-c the same as SS-31?
No. SS-31 is another name for elamipretide, a different peptide studied for mitochondrial effects. The US medicine Forzinity received accelerated approval for a specific Barth-syndrome indication and eligible patients; that approval does not extend to MOTS-c or to general anti-ageing. A shared interest in mitochondria does not prove that the two products work alike or that a combination works better. Read the SS-31 evidence and approval details. For the separate SS-31 fatigue studies, see what was measured in people.52
What is known about safety and product quality?
The FDA’s July 2026 review identified no publicly available clinical studies giving MOTS-c-related bulk substances to people in its evaluation and described major safety-data gaps. The FDA did not identify clinical studies describing how administered MOTS-c is handled in the human body. Its safety during pregnancy or breastfeeding and its interactions with medicines therefore remain uncertain. It raised concerns about identity, impurities and possible immune reactions for proposed compounded products; an uncertain risk is not proof that a particular harm occurs. The FDA also found no reports for MOTS-c in its adverse-event reporting system, but cautioned that reporting is voluntary and incomplete, so this does not establish safety. Naturally occurring MOTS-c also does not establish that an outside product is safe. See why identity, storage and sterility are separate questions.2
What does the US policy say?
An October 2026 HHS draft interim enforcement-discretion policy includes MOTS-c acetate for specified injectable forms under detailed Section 503A conditions. HHS cited additional quality information and a trial of a related analogue as part of its rationale. That policy is not FDA approval, and an analogue is not the same substance: neither establishes effectiveness or safety for a particular MOTS-c product. Rules and access elsewhere differ. Learn how to read claims about peptide products. For what the analogue study actually found, see CB4211, MOTS-c and the human trial. For the conditions and the separate 2027 advisory discussion, see the US policy guide.32
What if I compete in tested sport?
The World Anti-Doping Agency’s 2026 list names MOTS-c among metabolic modulators prohibited at all times under its rules. Sporting rules and medicine approvals are separate questions; check the current list and your anti-doping organisation’s guidance. Read the practical sports guide.4
Sources, kept close.
Selected supporting sources; this is not a complete literature review.
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasisNature Communications / PubMed Central · Primary human observation and mouse experiments
- July 2026 Pharmacy Compounding Advisory Committee: MOTS-c presentationU.S. Food and Drug Administration · Regulator advisory committee briefing presentation
- HHS interim enforcement-discretion policy and Appendix BU.S. Department of Health and Human Services · Interim enforcement policy and substance-specific justification
- 2026 Prohibited ListWorld Anti-Doping Agency · International sport anti-doping standard
- FDA Grants Accelerated Approval to First Treatment for Barth SyndromeU.S. Food and Drug Administration · US regulatory approval announcement, 2025